Gil Awada: How Neoadjuvant Immunotherapy is Reshaping the Treatment Landscape Across Solid Tumours
Gil Awada, Medical Oncologist at UZ Brussel, shared a post on LinkedIn:
“I’m incredibly proud to share our publication in Nature Cancer
In this review, we explore how neoadjuvant immunotherapy is reshaping the treatment landscape across solid tumours, highlighting its superiority over adjuvant approaches in selected indications, and discussing clinical data, biological rationale, and future directions.
This work would not have been possible without the expertise and dedication of an outstanding team Michiel van der Heijden, Prof Dr Christian Blank, Tina Cascone. I would like to especially thank Myriam Chalabi and Marleen Kok for their invaluable mentorship and guidance throughout this process!
Grateful to work alongside such passionate colleagues who are driving innovation in cancer immunotherapy.”
Title: The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Authors: Gil Awada, Tina Cascone, Michiel S. van der Heijden, Christian U. Blank, Marleen Kok, Myriam Chalabi
Read the Full Article on Nature Cancer
More posts featuring Neoadjuvant Immunotherapy.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023